Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer

Nature Reviews Clinical Oncology

Volumn 8, Issue 2, 2011, Pages 107-113

  Thoms, John ^a   Goda, Jayant S ^b   Zlotta, Alexender R ^a   Fleshner, Neil E ^a   Van Der Kwast, Theodorus H ^a   Supiot, Stéphane ^c   Warde, Padraig ^a   Bristow, Robert G ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TATA MEMORIAL HOSPITAL   (India)

^c CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADJUVANT THERAPY; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTRAOPERATIVE RADIOTHERAPY; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; RADIATION SAFETY; RECTUM INJURY; REVIEW; SURGICAL MORTALITY; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT FAILURE; URETHRA INJURY; URETHRA STRICTURE;

CLINICAL TRIALS AS TOPIC; HUMANS; MALE; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK FACTORS;

EID: 79551603389     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.207     Document Type: Review

References (48)

1. NCI. Prostate Cancer Treatment: Stage III prostate cancer [online], http://www.cancer.gov/ cancertopics.
2. Johansson, J. E., Holmberg, L., Johansson, S., Bergstr, R. & Adami, H. O. Fifteen-year survival in prostate cancer. A prospective, populationbased study in Sweden. JAMA 277, 467-471 (1997). (Pubitemid 27074330)
3. Heidenreich, A. et al. EAU guidelines on prostate cancer. Eur. Urol. 53, 68-80 (2008).
4. National Comprehensive Cancer Network. Clinical Practice Guidelines [online], http://www.nccn.org.
5. Bolla, M. et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366, 572-578 (2005).
6. Thompson, I. M. Jr et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 2329-2335 (2006).
7. Thompson, I. M. et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J. Urol. 181, 956-962 (2009).
8. Wiegel, T. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate specific antigen: (ARO 96-02/AUO AP 09/95). J. Clin. Oncol. 27, 2924-2930 (2009).
9. Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103-106 (2002).
10. Bolla, M. et al. Ten-year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study. Int. J. Radiat. Oncol. Biol. Phys. 72, S30-S31 (2008).
11. Carver, B. S., Bianco, F. J. Jr, Scardino, P. T. & Eastham, J. A. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J. Urol. 176, 564-568 (2006).
12. Gerber, G. S. et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur. Urol. 32, 385-390 (1997).
13. Hanks, G. E. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol. 21, 3972-3978 (2003).
14. Hsu, C. Y., Joniau, S., Oyen, R. , Roskams, T. & Van Poppel, H. Outcome of surgery for clinical unilateral T3a prostate cancer: a singleinstitution experience. Eur. Urol. 51, 121-128 (2007).
15. Lawton, C. A. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 49, 937-946 (2001).
16. Lerner, S. E., Blute, M. L. & Zincke, H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J. Urol. 154, 1447-1452 (1995).
17. Pilepich, M. V. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243-1252 (2001).
18. Roach, M. 3rd et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26, 585-591 (2008).
19. Ward, J. F., Slezak, J. M., Blute, M. L., Bergstralh, E. J. & Zincke, H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostatespecific antigen testing: 15-year outcome. BJU Int. 95, 751-756 (2005).
20. Bayley, A. et al. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 77, 477-483 (2009).
21. Heidenreich, A. & Ohlmann, C. H. The role of pelvic lymphadenectomy in the therapy of prostate and bladder cancer [German]. Aktuelle Urol. 36, 219-229 (2005). (Pubitemid 40991992)
22. Swanson, G. P. et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J. Clin. Oncol. 25, 2225-2229 (2007).
23. van der Kwast, T. H. et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J. Clin. Oncol. 25, 4178-4186 (2007).
24. van der Kwast, T. H., Collette, L. & Bolla, M. Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer. J. Clin. Oncol. 25, 5671-5672 (2007).
25. Klotz, L. H. et al. Long-term follow up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J. Urol. 170, 791-794 (2003).
26. Yee, D. S. et al. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int. 105, 185-190 (2010).
27. Carson, C. C. 3rd, Zincke, H., Utz, D. C., Cupps, R. E. & Farrow, G. M. Radical prostatectomy after radiotherapy for prostatic cancer. J. Urol. 124, 237-239 (1980).
28. Garzotto, M., Hung., A., Beer, T. F. & Farris, P. Phase I study of preoperative radiation and docetaxel for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 75 (Suppl. 3), S13 (2009).
29. Koontz, B. F. et al. Preliminary results of a phase I trial of preoperative radiotherapy for high-risk localized prostate cancer [abstract 78]. ASCO Genitourinary Cancers Symposium (2009).
30. Krengli, M. A. et al. Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects. Int. J. Radiat. Oncol. Biol. Phys. 76, 1073-1077 (2010).
31. Rocco, B. et al. Intraoperative radiotherapy during radical prostatectomy for intermediaterisk to locally advanced prostate cancer: treatment technique and evaluation of perioperative and functional outcome vs standard radical prostatectomy, in a matchedpair analysis. BJU Int. 104, 1624-1630 (2009).
32. Supiot, S. et al. A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiother. Oncol. 88, 53-60 (2008).
33. Fowler, J. F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 44, 265-276 (2005).
34. [No authors listed] Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N. Engl. J. Med. 336, 980-987 (1997).
35. Birgisson, H., Pahlman, L., Gunnarsson, U., Glimelius, B. & Swedish Rectal Cancer Trial Group. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J. Clin. Oncol. 23, 8697-8705 (2005).
36. Folkesson, J. et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J. Clin. Oncol. 23, 5644-5650 (2005).
37. Kapiteijn, E. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345, 638-646 (2001).
38. Peeters, K. C. et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 246, 693-701 (2007).
39. Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731-1740 (2004).
40. Sebag-Montefiore, D. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373, 811-820 (2009).
41. O'Sullivan, B. et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359, 2235-2241 (2002).
42. Zelefsky, M. J. et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int. J. Radiat. Oncol. Biol. Phys. 71, 1028-1033 (2008).
43. Thoms, J., Bristow, R., Warde, P. & Supiot, S. Response to "Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects" (Int J Radiat Oncol Biol Phys 2009; in press). Int. J. Radiat. Oncol. Biol. Phys. 76, 1277 (2009).
44. Hotte, S. J., Winquist, E. W., Stitt, L. & Chambers, A. F. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95, 506-512 (2002).
45. Russo, A. L. et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin. Cancer Res. 15, 4292-4298 (2009).
46. Lapointe, J. et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 67, 8504-8510 (2007).
47. Reid, A. H. et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer 102, 678-684 (2010).
48. Vickers, A. J. et al. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur. Urol. 53, 960-966 (2008).